An Extraordinary General Meeting of Targovax ASA will be held at the Company's offices at Lysaker, on 30 November 2017 at 13:00 CET.
Please find the notice including agenda for the Extraordinary General Meeting and appendices attached to this disclosure. The notice will also be sent to all shareholders. The notice and appendices will also be made available on Targovax' website www.targovax.com under Corporate Governance and General Meetings.
Notice of attendance must be received no later than 29 November 2017 at 16:00 CET.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: [email protected]
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/fcacf98b-f8fb-40f6-b822-191b62ad0730


Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 



